Allogene Therapeutics, Inc. (ALLO) Discusses Interim Futility Analysis from Pivotal Phase II ALPHA 3 Trial in First-Line Consolidation Large B-Cell Lymphoma - Slideshow

Allogene Therapeutics presented interim futility analysis results from its Phase II ALPHA 3 trial evaluating CAR-T therapy in first-line consolidation for large B-cell lymphoma. The analysis assessed whether the trial met predefined efficacy thresholds for continuation, with data reviewed by an independent monitoring committee in early 2026. Preliminary findings suggest the therapy did not demonstrate sufficient efficacy to justify proceeding as planned, raising questions about its viability in this patient population. The company will determine next steps, including potential trial modifications or discontinuation, based on the committee’s recommendations and broader clinical strategy. Investors and clinicians await further details on safety, secondary endpoints, and implications for Allogene’s pipeline and the broader CAR-T landscape.